Evidence that the axolemmal mitogen for cultured Schwann cells is a positively charged, heparan sulfate proteoglycan-bound, heparin-displaceable molecule.
Treatment of axolemma with pH 9 buffer results in a pellet enriched two-fold in the mitogen for cultured Schwann cells. Heparitinase treatment releases 8% of the mitogen into solution, while heparin selectively solubilizes the mitogen, resulting in an extract which has a specific mitogenic activity approximately 2.5 times greater than the mitogenicity of the starting axolemma membrane. These data support a model in which the axolemmal mitogen is a positively charged molecule associated with negatively charged sulfated proteoglycans.
DeCoster
M A
MA
Dept. of Biochemistry and Molecular Biophysics, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
DeVries
G H
GH
D000818:Animals; D001369:Axons / Q000378:metabolism*; D001933:Brain Stem; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D006025:Glycosaminoglycans / Q000378:metabolism*; D019812:Heparan Sulfate Proteoglycans; D006493:Heparin / Q000378:metabolism*; D006497:Heparan Sulfate / Q000378:metabolism*; D008934:Mitogens / Q000032:analysis* / Q000494:pharmacology; D011509:Proteoglycans / Q000378:metabolism*; D051381:Rats; D012583:Schwann Cells / Q000166:cytology* / Q000187:drug effects
D011508:Chondroitin Sulfate Proteoglycans; D006025:Glycosaminoglycans; D019812:Heparan Sulfate Proteoglycans; D006493:Heparin; D006497:Heparan Sulfate; D008934:Mitogens; D011509:Proteoglycans